An Itovebi regimen demonstrated significantly longer progression-free survival compared with placebo in some with metastatic ...

A retrospective study revealed differences in metastasis patterns and treatment utilization by ethnicity among patients with breast cancer and brain metastasis.

Boston Scientific Corporation BSX has entered into a definitive agreement to acquire Intera Oncology Inc., a Boston-based life science company. The acquisition expands the company’s interventional ...

A team of researchers led by Professor Ningling Kang, PhD, at The Hormel Institute, University of Minnesota, has published an ...

Intera makes a pump and a chemotherapy drug to treat liver tumors. Boston Scientific sees the purchase as a way to provide ...

Boston Scientific has signed a deal to acquire the maker of a chemotherapy infusion pump aimed at treating certain inoperable ...

Boston Scientific (NYSE:BSX) has agreed to acquire medical device maker Intera Oncology for an undisclosed amount, with the ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

Boston Scientific (NYSE:BSX) announced today that it agreed to acquire infusion pump maker Intera Oncology for an undisclosed ...

Boston Scientific Corp. (BSX) announced Monday it has entered into a definitive agreement to acquire Intera Oncology Inc., a ...

China NMPA accepts Akeso's sNDA penpulimab combination therapy for first-line treatment of hepatocellular carcinoma: Hong Kong Monday, November 25, 2024, 13:00 Hrs [IST] Akeso, In ...